Fred Alger Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Fred Alger Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,331,759	Closed	-$143M	–	585
2023 Q1	$143M	Sell	1,331,759 -27,497	-2%	-$3.16M	0.76%	24
2022 Q4	$150M	Buy	1,359,256 +323,091	+31%	+$21M	0.81%	26
2022 Q3	$61.1M	Buy	1,036,165 +792,620	+325%	+$36.3M	0.31%	94
2022 Q2	$6.88M	Buy	243,545 +110,787	+83%	+$3.21M	0.03%	237
2022 Q1	$5.01M	Sell	132,758 -39,663	-23%	-$1.57M	0.02%	270
2021 Q4	$6.82M	Buy	+172,421	New	+$5.4M	0.02%	264

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Fred Alger Management's RXDX Position: Q2 2023 in Review

Fred Alger Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,331,759 shares — an estimated $143M sold.

Fred Alger Management first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $150M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Fred Alger Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Fred Alger Management sold 1,331,759 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $143M.
Fred Alger Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Fred Alger Management's Prometheus Biosciences, Inc. Common Stock position peaked at $150M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Fred Alger Management's 13F filing for Q2 2023, filed 14 Aug 2023.